You are here:
The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide.…
Heinrich Wieland Prize for Matthias Tschöp: Breakthrough in the battle against obesity and diabetes
Diabetes researcher Dr. Timo Müller was honored with the 58th Minkowski Prize awarded by the EASD for his distinction manifested by publications that contribute to the advancement of knowledge concerning diabetes.
For major breakthroughs, the American Diabetes Association (ADA) awards its highest honor, the Banting Medal for Scientific Achievement named after the nobel laureate and discoverer of insulin, Frederick Banting. Helmholtz Munich CEO and Humboldt…
Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors…
The German Diabetes Society (DDG) awards this year's Werner Creutzfeldt Prize to Helmholtz Munich scientist PD Dr Timo Müller for his exceptional work in the research field of Incretin-based diabetes and obesity. This is already the second time in a…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
